US Stock Movement: 10x Genomics plunged on October 12 due to high valuations, profit-taking, and ARK’s reduction of holdings

10x Genomics October 12 Sharp Decline Analysis

Keywords: High Valuation, Profit Taking, ARK Reduction

1. As of October 12, 2026, available information does not indicate any new operational or regulatory negatives for the company; after a cumulative year-to-date stock price increase of 359.12% and a 23.39% decline over the past 5 days, the stock continues its correction from a high level amid significant profit taking pressure.

2. On October 6, 2026, the ARK investment portfolio reduced its holdings of 10x Genomics stock, increasing short-term supply pressure; given the substantial gains within the year, institutional portfolio adjustments may further intensify selling pressure.

3. On October 5, 2026, data showed the company’s stock price at approximately $93.50, higher than the narrative valuation of about $62.13; expectations from Atera commercial shipment and Sentira platform release have been partially priced in, increasing the risk of a valuation pullback.

(Disclaimer: This content has been summarized using AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)